No­vo Nordisk con­tin­ues to stack obe­si­ty pipeline, this time with Swiss ze­brafish biotech

No­vo Nordisk li­censed an ex­per­i­men­tal obe­si­ty pill from Er­a­Cal Ther­a­peu­tics in a deal worth €235 mil­lion, or rough­ly $255 mil­lion, as it hunts for the next gen­er­a­tion of weight man­age­ment med­i­cines.

Un­like No­vo’s wide­ly-known weight loss in­jec­tion We­govy, the Er­a­Cal pro­gram is an oral small mol­e­cule. It “is be­lieved to tar­get a nov­el mech­a­nism of ac­tion con­trol­ling ap­petite and body weight to treat obe­si­ty,” Er­a­Cal said in a press re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER